Phase II HDM-SPIRE Safety & Efficacy Study

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05560698` - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment	N/A
Completed	`NCT02849210` - A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea	Phase 1
Completed	`NCT02340130` - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma	Phase 2
Completed	`NCT01923792` - ToleroMune House Dust Mite Follow on Study	N/A
Completed	`NCT01949441` - ToleroMune House Dust Mite (HDM) Tolerability Study	Phase 2
Completed	`NCT01949415` - An Optional Investigation of Biomarkers of Efficacy	N/A
Completed	`NCT01949428` - House Dust Mite Observational Study	N/A
Completed	`NCT01447784` - ToleroMune House Dust Mites (HDM) Exposure Chamber Study	Phase 2
Recruiting	`NCT04435990` - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites	Phase 3
Active, not recruiting	`NCT05960266` - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study	Early Phase 1
Completed	`NCT01620762` - Phase III Cat-PAD Study	Phase 3
Completed	`NCT01720251` - Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy	Phase 2
Completed	`NCT01448603` - ToleroMune Ragweed Follow up Study	N/A
Completed	`NCT01353755` - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma	Phase 3
Completed	`NCT00574210` - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)	Phase 2
Completed	`NCT00537342` - Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)	Phase 3
Completed	`NCT00540631` - Multicenter Trial of Immunotherapy With House Dust Mite Allergoid	Phase 3
Completed	`NCT05540717` - Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen	Phase 3
Completed	`NCT02844842` - Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Completed	`NCT01734265` - Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).	Phase 2

NCT number	NCT02150343
Study type	Interventional
Source	Circassia Limited
Contact
Status	Completed
Phase	Phase 2
Start date	September 2014
Completion date	April 13, 2017

Phase II HDM-SPIRE Safety and Efficacy Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms